VEXAS is a prototypic hemato-inflammatory disease combining rheumatologic and hematologic disorders in a molecularly defined nosological entity. In this nationwide study, we aimed at screenshotting the current diagnostic capabilities and clinical-genomic features of VEXAS, and tracked UBA1 longitudinal clonal dynamics upon different therapeutics, including allogeneic hematopoietic cell transplant. We leveraged a collaboration between the Italian Society of Experimental Hematology and of Rheumatology and disseminated a national survey to collect clinical and molecular patient information. Overall, 13/29 centers performed UBA1 genomic testing locally, including Sanger sequencing (46%), next-generation sequencing (23%), droplet digital polymerase chain reaction (8%), or combination (23%). A total of 41 male patients were identified, majority (51%) with threonine substitutions at Met41 hotspot, followed by valine and leucine (27% and 8%). Median age at VEXAS diagnosis was 67 years. All patients displayed anemia (median hemoglobin 9.1 g/dL), with macrocytosis. Bone marrow vacuoles were observed in most cases (89%). The most common rheumatologic association was polychondritis (49%). A concomitant myelodysplastic neoplasm/syndrome (MDS) was diagnosed in 71% of patients (n = 28), chiefly exhibiting lower Revised International Prognostic Scoring System risk profiles. Karyotype was normal in all patients, except three MDS cases showing -Y, t(12;16)(q13;q24), and +8. The most frequently mutated gene was DNMT3A (n = 10), followed by TET2 (n = 3). At last follow-up, five patients died and two patients progressed to acute leukemia. Longitudinal UBA1 clonal dynamics demonstrated mutational clearance following transplant. We collected a nationwide interdisciplinary VEXAS patient cohort, characterized by heterogeneous rheumatologic manifestations and treatments used. MDS was diagnosed in 71% of cases. Patients exhibited various longitudinal UBA1 clonal dynamics.

Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort / Gurnari, C.; Pascale, M. R.; Vitale, A.; Diral, E.; Tomelleri, A.; Galossi, E.; Falconi, G.; Bruno, A.; Crisafulli, F.; Frassi, M.; Cattaneo, C.; Bertoli, D.; Bernardi, M.; Condorelli, A.; Morsia, E.; Poloni, A.; Crisa, E.; Caravelli, D.; Triggianese, P.; Brussino, L.; Battipaglia, G.; Bindoli, S.; Sfriso, P.; Caroni, F.; Dragani, M.; Mallegni, F.; Pilo, F.; Firinu, D.; Curti, A.; Papayannidis, C.; Olivieri, A.; Kordasti, S.; Albano, F.; Pane, F.; Musto, P.; Bocchia, M.; Lugli, E.; Breccia, M.; Frigeni, M.; Dagna, L.; Greco, R.; Franceschini, F.; Campochiaro, C.; Cantarini, L.; Voso, M. T.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 99:2(2024), pp. 254-262. [10.1002/ajh.27169]

Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort

Battipaglia G.
Membro del Collaboration Group
;
Pane F.;
2024

Abstract

VEXAS is a prototypic hemato-inflammatory disease combining rheumatologic and hematologic disorders in a molecularly defined nosological entity. In this nationwide study, we aimed at screenshotting the current diagnostic capabilities and clinical-genomic features of VEXAS, and tracked UBA1 longitudinal clonal dynamics upon different therapeutics, including allogeneic hematopoietic cell transplant. We leveraged a collaboration between the Italian Society of Experimental Hematology and of Rheumatology and disseminated a national survey to collect clinical and molecular patient information. Overall, 13/29 centers performed UBA1 genomic testing locally, including Sanger sequencing (46%), next-generation sequencing (23%), droplet digital polymerase chain reaction (8%), or combination (23%). A total of 41 male patients were identified, majority (51%) with threonine substitutions at Met41 hotspot, followed by valine and leucine (27% and 8%). Median age at VEXAS diagnosis was 67 years. All patients displayed anemia (median hemoglobin 9.1 g/dL), with macrocytosis. Bone marrow vacuoles were observed in most cases (89%). The most common rheumatologic association was polychondritis (49%). A concomitant myelodysplastic neoplasm/syndrome (MDS) was diagnosed in 71% of patients (n = 28), chiefly exhibiting lower Revised International Prognostic Scoring System risk profiles. Karyotype was normal in all patients, except three MDS cases showing -Y, t(12;16)(q13;q24), and +8. The most frequently mutated gene was DNMT3A (n = 10), followed by TET2 (n = 3). At last follow-up, five patients died and two patients progressed to acute leukemia. Longitudinal UBA1 clonal dynamics demonstrated mutational clearance following transplant. We collected a nationwide interdisciplinary VEXAS patient cohort, characterized by heterogeneous rheumatologic manifestations and treatments used. MDS was diagnosed in 71% of cases. Patients exhibited various longitudinal UBA1 clonal dynamics.
2024
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort / Gurnari, C.; Pascale, M. R.; Vitale, A.; Diral, E.; Tomelleri, A.; Galossi, E.; Falconi, G.; Bruno, A.; Crisafulli, F.; Frassi, M.; Cattaneo, C.; Bertoli, D.; Bernardi, M.; Condorelli, A.; Morsia, E.; Poloni, A.; Crisa, E.; Caravelli, D.; Triggianese, P.; Brussino, L.; Battipaglia, G.; Bindoli, S.; Sfriso, P.; Caroni, F.; Dragani, M.; Mallegni, F.; Pilo, F.; Firinu, D.; Curti, A.; Papayannidis, C.; Olivieri, A.; Kordasti, S.; Albano, F.; Pane, F.; Musto, P.; Bocchia, M.; Lugli, E.; Breccia, M.; Frigeni, M.; Dagna, L.; Greco, R.; Franceschini, F.; Campochiaro, C.; Cantarini, L.; Voso, M. T.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 99:2(2024), pp. 254-262. [10.1002/ajh.27169]
File in questo prodotto:
File Dimensione Formato  
2023 - Gurnari - Diagnostic capabilities clinical features and longitudinal UBA1 clonal dynamics of- American J Hematol.pdf

accesso aperto

Licenza: Non specificato
Dimensione 2.16 MB
Formato Adobe PDF
2.16 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/993402
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 41
social impact